In January 2024, Washington University in St. Louis (WashU) and healthcare investment firm, Deerfield Management, announced a research and development collaboration to help bring next-generation therapeutics to market.
Through a newly launched company called VeritaScience, LLC, Deerfield has committed up to $130 million over a 10-year period and may provide WashU scientists with both funding and functional expertise to advance biomedical research.